Cytosorbents CorpCTSO
About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Employees: 186
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
2.23% less ownership
Funds ownership: 30.18% [Q3] → 27.95% (-2.23%) [Q4]
4% less funds holding
Funds holding: 52 [Q3] → 50 (-2) [Q4]
42% less capital invested
Capital invested by funds: $24.6M [Q3] → $14.2M (-$10.4M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
D. Boral Capital Jason Kolbert 26% 1-year accuracy 72 / 279 met price target | 835%upside $10 | Buy Maintained | 25 Feb 2025 |
Financial journalist opinion









